01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
We know August was exhausting for employers – New York, New Jersey, Maine, Colorado, and yes, even ...
Read More >
Title I of the Americans with Disabilities Act (ADA) prohibits employment discrimination on the basi...
Read More >
For many years, the development industry in Florida has been able to extend building permits, develo...
Read More >
In a striking blow, stripping a city of a judgment of nearly $1 million, the Massachusetts Appeals C...
Read More >
A recent decision from the Massachusetts Supreme Judicial Court, the highest court of Massachusetts,...
Read More >
On December 17, 2019, the National Labor Relations Board (“Board”) ruled that an employer’s rule ...
Read More >